Journal article
Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction
Abstract
BACKGROUND: The potential benefit of dual antiplatelet therapy beyond 1 year after a myocardial infarction has not been established. We investigated the efficacy and safety of ticagrelor, a P2Y12 receptor antagonist with established efficacy after an acute coronary syndrome, in this context.
METHODS: We randomly assigned, in a double-blind 1:1:1 fashion, 21,162 patients who had had a myocardial infarction 1 to 3 years earlier to ticagrelor at a …
Authors
Bonaca MP; Bhatt DL; Cohen M; Steg PG; Storey RF; Jensen EC; Magnani G; Bansilal S; Fish MP; Im K
Journal
The New England Journal of Medicine, Vol. 372, No. 19, pp. 1791–1800
Publisher
Massachusetts Medical Society
Publication Date
May 7, 2015
DOI
10.1056/nejmoa1500857
ISSN
0028-4793
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AdenosineAgedAspirinCardiovascular DiseasesDouble-Blind MethodDrug Administration ScheduleDrug Therapy, CombinationFemaleHemorrhageHumansIntracranial HemorrhagesKaplan-Meier EstimateMaleMiddle AgedMyocardial InfarctionPlatelet Aggregation InhibitorsPurinergic P2Y Receptor AntagonistsRiskSecondary PreventionTicagrelor